EP2089530B1 - Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus - Google Patents

Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus Download PDF

Info

Publication number
EP2089530B1
EP2089530B1 EP07822458A EP07822458A EP2089530B1 EP 2089530 B1 EP2089530 B1 EP 2089530B1 EP 07822458 A EP07822458 A EP 07822458A EP 07822458 A EP07822458 A EP 07822458A EP 2089530 B1 EP2089530 B1 EP 2089530B1
Authority
EP
European Patent Office
Prior art keywords
formula
seq
enzyme
compound
azoarcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07822458A
Other languages
German (de)
English (en)
Other versions
EP2089530A2 (fr
Inventor
Michael Breuer
Hansgeorg Ernst
Bernhard Hauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to EP07822458A priority Critical patent/EP2089530B1/fr
Publication of EP2089530A2 publication Critical patent/EP2089530A2/fr
Application granted granted Critical
Publication of EP2089530B1 publication Critical patent/EP2089530B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P23/00—Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group

Definitions

  • the present invention relates to a process for the preparation of optically active (4S) -4-hydroxy-2,6,6-trimethyl-cyclohex-2-en-1-one derivatives of the formula (I) and to a process for the preparation of ( 3S, 3'S) -Astaxanthin of formula (III) comprising the former method.
  • Astaxanthin (3,3'-dihydroxy- ⁇ , ⁇ '-carotene-4,4'-dione) can be present in the form of the following configuration isomers because of its two chiral centers in the 3 and 3'-positions: (3S, 3'S), (3R, 3'R), (3S, 3'R) and (3R, 3'S).
  • the latter two configuration isomers are identical and represent a meso-form (Carotenoids Handbook, 2004, Main List No. 405).
  • Another synthetic strategy is to arrive at enantiomerically pure synthesis units via microbial or enzymatic processes ( Helvetica Chimica Acta, 1978, 61, 2609 . Helvetica Chimica Acta, 1981, 64, 2405 ) Since these building blocks are too low in oxidation state, they had to be converted into (S, S) -astaxanthin precursors in multistep syntheses.
  • WO 2006/039685 describes, on the one hand, in Scheme II, a two-stage enantioselective hydrogenation of ketoisophorone to an enantiomerically pure C9-diol, from which, after re-oxidation of a hydroxy group based on the in Helv. Chim. Acta, 1978 61, 2609 described method in a multi-step synthesis to (S, S) -Astaxanthin precursors passes. Further describes WO 2006/039685 an enantioselective catalytic transfer hydrogenation of a C9 enol ether of the formula (IIa) to the corresponding enantiomerically pure alcohol of the formula (Ia).
  • Suitable hydrogenation catalysts are metals with chiral ligands, preferably ruthenium catalysts with optically active amines as ligands. Disadvantageous this method is that an O-protected derivative of a technical intermediate of the formula (IIb) is used, which requires additional synthetic effort. In addition, the required optically active catalysts are very expensive, so that their use in technical processes is difficult from an economic point of view.
  • dehydrogenases are suitable as biocatalysts for the preparation of optically active hydroxy compounds. These are well characterized biocatalysts already used in a number of technical processes ( Angew. Chem. Int. Ed., 2004, 43, 788 . Tetrahedron, 2004, 60, 633 . Chiral Catalysis - Asymmetric Hydrogenation Supplement to Chemistry Today, 2004, 22, 26 . Current Opinion in Chemical Biology, 2004, 8, 120 . Organic Process Research & Development, 2002, 6, 558 . Tetrahedron: Asymmetry, 2003, 14, 2659 . Chiral catalysis asymmetric hydrogenation supplement to Chemistry Today, 2004, 22, 43 ).
  • WO 2005/108590 describes a process for preparing certain optically active alkanols, such as (1S) -3-methylamino-1- (2-thienyl) -propan-1-ol or (1S) -3-chloro-1- (2-thienyl) - Propan-1-ol, described by enzymatic reduction of the corresponding ketones. To what extent the enzymes used for the reduction of structurally different types of ketones are useful, is not discussed.
  • R 1 is hydrogen, C 1 -C 10 -alkyl, such as, for example, methyl, ethyl, n-propyl, isopropyl or n-hexyl, C 7 -C 14 -Arylalkyl, such as benzyl, an alkali metal M 1 or an alkaline earth metal fragment M 2 1/2 or (M 2 ) + X-, where M 1 is Li, Na, K, Rb or Cs, preferably Na or K, in particular Na and M 2 is Mg, Ca, Sr or Ba, especially Mg, and X- is a singly charged anion such as halide, acetate or dihydrogen phosphate.
  • R 1 is hydrogen, methyl, Na or K, more preferably hydrogen, methyl or Na, in particular hydrogen or sodium.
  • the radical R 2 is identical or different from R 1 and is hydrogen, C 1 -C 10 -alkyl, such as, for example, methyl, ethyl, n-propyl iso-propyl or n-hexyl, C 7 -C 14 -arylalkyl, such as, for example, benzyl, an alkali metal M 1 or an alkaline-earth metal fragment M 2 1/2 or (M 2 ) + X-, where M 1 is Li, Na, K, Rb or Cs, preferably Na or K, in particular Na and M 2 is Mg, Ca, Sr or Ba, in particular Mg and X is a singly charged anion, such as halide, acetate or dihydrogen phosphate.
  • R 1 is hydrogen, methyl, Na or K, more preferably hydrogen, methyl or Na, in particular hydrogen or sodium.
  • E oxidoreductases
  • ie in particular enzymes with dehydrogenase activity are, in particular, the enzymes of the families of aldo-keto-reductases of the aldo-keto-reductase superfamily ( KMBohren, B.Bullock, B.Wermuth and KHGabbay J.Biol. Chem. 1989, 264, 9547-9551 ) and the short-chain alcohol dehydrogenases / reductases (shortchain alcohol dehydrogenases / reductases [SDR]).
  • the alcohol dehydrogenases in particular the short-chain alcohol dehydrogenases, are particularly suitable. Particularly suitable among the alcohol dehydrogenases are the enzymes which, with NADH or NADPH as reduction equivalents, reduce the compound of the formula (II) to the compound of the formula (I).
  • Suitable enzymes (E) having oxidoreductase activity, in particular dehydrogenase activity, which comprise an amino acid sequence according to SEQ ID NO: 2, and "functional equivalents" or analogues of the specifically disclosed enzymes (E) having oxidoreductase activity, in particular dehydrogenase activity, which can also be used in the process are described in detail in WO 2005/108590 , Page 11 to 16, which is incorporated herein by reference.
  • the phenylethanol dehydrogenase from Azoarcus sp EbN1 can be classified as short-chain alcohol dehydrogenases / reductases (SDRs).
  • SDRs short-chain alcohol dehydrogenases / reductases
  • the enzyme group is described in detail in H.Jörnvall, B.Persson, M.Krook, S.Atrian, R.Gonzalez-Duarte, J.Jeffery and D.Ghosh, Biochemistry, 1995, 34, pp. 6003-6013 or U. Obpermann, C. Filling, M. Hult, N. Shafqat, XQWu, M. Lindh, J. Shafqat, E. Nordling, Y. Kallberg, B.
  • Azoarcus species are Azoarcus anaerobius, Azoarcus buckelii, Azoarcus communis, Azoarcus evansii, Azoarcus indigens, Azoarcus toluclasticus, Azoarcus tolulyticus, Azoarcus toluvorans, Azoarcus sp., Azoarcus sp. 22Lin, Azoarcus sp. BH72, Azoarcus sp. CC-11, Azoarcus sp. CIB, Azoarcus sp. CR23, Azoarcus sp. EB1, Azoarcus sp. EbN1, Azoarcus sp.
  • the inventive method is preferably carried out in the presence of an enzyme (E), wherein the enzyme is encoded by a nucleic acid sequence according to SEQ ID NO: 1 or a functional equivalent thereof.
  • the enzyme with dehydrogenase activity is selected from enzymes which comprise an amino acid sequence according to SEQ ID NO: 2 or a sequence derived therefrom in which up to 25%, preferably up to 20%, particularly preferably up to in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2.1% of the amino acid residues have been altered by a deletion, a substitution, an insertion or a combination of deletion, substitution and insertion; the polypeptide sequences which are modified compared to SEQ ID NO: 2 still possess at least 50%, preferably 65%, particularly preferably 80%, in particular more than 90%, of the enzymatic activity of SEQ ID NO: 2.
  • the enzymatic activity of SEQ ID NO: 2 is to be understood as the ability to add the ketones of the formula (II), in particular with R 1 HH or Na enantioselectively, to the (S) -alcohol having the general formula (I) to reduce.
  • the process according to the invention is carried out with the addition of reducing equivalents, in particular NADH or NADPH, which serve as hydride source. Since NADH or NADPH are very expensive compounds, these reduction equivalents are usually used only in catalytic amounts.
  • the reducing agent (RM) inorganic or organic compounds for example phosphites or alcohols, or else electrochemical processes, such as reduction at a cathode.
  • the preferred reducing agent (RM) is an organic compound which is at least contains a primary or secondary alcohol function CH (OH), such as isopropanol, 2-butanol, 2-pentanol, 2-hexanol, 3-hexanol or reducing sugars such as glucose, in particular isopropanol or glucose.
  • CH primary or secondary alcohol function
  • the reducing agent (RM) is reacted with the aid of the enzyme (E) or another enzyme (E 2 ) to the oxidation product (OP), wherein the oxidation product (OP) is at least partially removed from the reaction medium or from the reaction equilibrium.
  • the reducing agent (RM) is a secondary alcohol, it is also often referred to as sacrificial alcohol and the correspondingly formed oxidation product (OP) as sacrificial ketone.
  • the added sacrificial alcohol is used not only for the regeneration of the spent reduction equivalents, but also as a co-solvent. It is possible to work in a liquid 1-phase, 2-phase or even multi-phase system, usually one consisting of water and / or one water-miscible solvent.
  • the reduction equivalents are preferably used in an amount of 0.001 to 100 mmol, more preferably from 0.01 to 1 mmol reduction equivalents per mole of trimethyl-cyclohex-2-en-1,4-dione derivative of the formula (II).
  • the formed oxidation product (OP) can be at least partially removed from the reaction medium or from the reaction equilibrium.
  • secondary alcohols such as isopropanol as a reducing agent (RM)
  • the removal of the so-called sacrificial ketones formed, acetone in the case of isopropanol as a sacrificial alcohol can be carried out in various ways, for example by selective membranes or by extraction or distillation processes.
  • the distillation is used to remove a ketone such as acetone.
  • a ketone such as acetone.
  • distillation losses are usually compensated by topping up the sacrificial alcohol and possibly the water.
  • the distillation rates are usually in a range from 0.02% / min to 2% / min, preferably from 0.05% / min to 1% / min, based on the reaction volume.
  • the jacket temperatures of the reactor are between 5 and 70 Kelvin, preferably between 10 and 40 Kelvin above the internal reactor temperature.
  • oxidation product As in the case of the oxidation of glucose to gluconic the latter is removed by cyclization to gluconolactone the reaction equilibrium between reducing agent (RM) and oxidizing agent (OM). While the oxidation of many sacrificial alcohols by the same enzyme (E) is possible, which also includes the reduction of compounds of formula (II) to compounds of the For the oxidation of glucose, a second enzyme (E 2 ), such as, for example, glucose dehydrogenase, has to be added.
  • the distillation is carried out particularly well in a pressure range of 1-500 mbar, preferably 10-200 mbar.
  • Expression constructs containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence encoding a protein useful in the method, ie an enzyme (E), as well as corresponding vectors comprising at least one of the expression constructs, are described in detail WO 2005/108590 , Pages 22 to 25, which is incorporated herein by reference.
  • Recombinant microorganisms transformed with a suitable vector or construct and used to produce the polypeptides useful in the method i. h of an enzyme (E) can be used in detail in WO 2005/108590 , Pages 25 to 27, which is incorporated herein by reference.
  • the polypeptides can also be produced on an industrial scale by the methods indicated.
  • the inventive method is advantageously carried out at a temperature between 0 ° C and 95 ° C, preferably between 10 ° C and 85 ° C, more preferably between 15 ° C and 75 ° C.
  • the pH in the process according to the invention is advantageously maintained between pH 4 and 12, preferably between pH 4.5 and 9, particularly preferably between pH 5 and 8.
  • Enantiomerically pure or chiral products or optically active alcohols are to be understood in the process according to the invention as enantiomers which show an enantiomeric enrichment.
  • growing cells can be used which contain suitable nucleic acids, nucleic acid constructs or vectors.
  • dormant or open cells can be used.
  • open cells is meant, for example, cells that have been rendered permeable through treatment with, for example, solvents, or cells that have been disrupted by enzyme treatment, mechanical treatment (e.g., French Press or ultrasound) or otherwise.
  • the crude extracts thus obtained are advantageously suitable for the process according to the invention.
  • Purified or purified enzymes (E) can also be used for the process.
  • immobilized microorganisms or enzymes that can be used advantageously in the reaction.
  • free organisms or enzymes are used for the process according to the invention, they are expediently removed before extraction, for example by filtration or centrifugation.
  • the compounds of the formula (I) prepared in the process according to the invention for example (3S) -3,4-dihydroxy-2,6,6-trimethylcyclohex-2-enone, can advantageously be obtained from the aqueous reaction solution by extraction or precipitation .
  • the product solution for separating undissolved biological material is first filtered, preferably with the addition of a filter aid such as Celite.
  • solvents examples include toluene or other cyclic or open-chain hydrocarbons, chlorinated hydrocarbons such as methylene chloride, ethyl or butyl acetate, and ethers such as MTBE or diisopropyl ether.
  • the product solution is first adjusted to a pH of 1 to 3, preferably pH 1.
  • the acidification is preferably carried out with mineral acids such as hydrochloric or sulfuric acid, more preferably with sulfuric acid.
  • the product precipitates and can be separated.
  • the acidic product solution is extracted several times with an organic solvent. Suitable solvents here are chlorinated hydrocarbons, in particular methylene chloride, ethers such as MTBE or disopropyl ether and ethyl acetate.
  • This extraction can be carried out batchwise or continuously.
  • the extraction of the product may be assisted by concentrating the aqueous phase before acidification or by "salting out"; however, these operations are not essential for the separation of the product from the reaction solution.
  • the product has a high enantiomeric purity of> 98% ee. It may be by crystallization according to Helv. Chim. Acta 64, 2436, 1981 be purified, but is preferably without further purification operation in the further synthesis of S, S-astaxanthin according to Helv. Chim. Acta 64, 2447, 1981 used.
  • the process according to the invention can be operated batchwise, semi-batchwise or continuously.
  • the process according to the invention can advantageously be carried out in bioreactors, as described, for example, in US Pat Biotechnology, Vol. 3, 2nd Ed., Rehm et al. Ed., (1993), especially Chapter II ,
  • a further subject matter of the present invention is a process for the preparation of (3S, 3'S) -astaxanthin of the formula (III) comprising the process described above for the preparation of optically active (4S) -4-hydroxy-2,6,6-trimethyl- cyclohex-2-en-1-one derivatives of the formula (I) as a reaction step of the overall synthesis of (3S, 3'S) -Astaxanthin.
  • optically active (4S) -4-hydroxy-2,6,6-trimethyl- cyclohex-2-en-1-one derivatives of the formula (I) as a reaction step of the overall synthesis of (3S, 3'S) -Astaxanthin.
  • the advantage of the method according to the invention lies in the recovery of compounds of formula (I) with high enantiomeric purity associated with good yields of these compounds.
  • E. coli LU11558 prepared as in WO 2005/108590 , Examples 1 and 2 were mixed in 20mL LB-Amp / Spec / Cm (100 ⁇ g / L ampicillin, 100 ⁇ g / L spectinomycin, 20 ⁇ g / L chloramphenicol), 0.1mM IPTG, 0.5g / L rhamnose in 100mL alder -meyer flask (baffled) for 18 h at 37 ° C, centrifuged at 5000 * g / 10min, washed once with 10 mM TRIS * HCl, pH 7.0, and resuspended in 2 mL of the same buffer.
  • Example 2 10 ⁇ L of cell-free crude extract (Example 1, approximately 10 mg / mL total protein) were incubated for 480 min in a mixture of 770 ⁇ L 50 mM K-phosphate buffer (with 1 mM MgCl 2 , pH 6.5), 100 ⁇ L i-propanol, 100 ⁇ L NADH Shaking incubated (0.5M) and 20 ⁇ L compound 1 (1M in DMSO). The batches were analyzed analogously to Example 3. On average, 0.13 mM of 3,4-dihydroxy-2,6,6-trimethylcyclohex-2-enone was formed. In control experiments without the addition of rhamnose at the time of cultivation, no turnover was detectable.
  • the educt and product concentration can be determined by HPLC. Depending on the choice of stationary and mobile phase, ee value can be determined in addition to the concentration.
  • stationary phase Chiralpak AS-RH, 150 * 4,6mm, Daicel, tempered to 40 ° C mobile phase: Mobile phase A: 10mM KH 2 PO 4 Eluent B: CH 3 CN Gradient: Time [min] A [%] B [%] Flow [ml / min] 0 90 10 0.5 10 90 10 0.5 11 60 40 0.5 20 60 40 0.5 Flow rate: 0.5 ml / min detection: UV detection at 260nm Retention times: (+) - 3,4-dihydroxy-2,6,6-trimethyl-cyclohex-2-enone: approx.
  • Authentic material is used to create a set of standards that can be used to determine the concentration of unknown samples and to allow assignment of the enantiomers.
  • glucose dehydrogenase For cofactor regeneration glucose dehydrogenase can be used.
  • the enzyme is available from commercial (e.g., Karl Fine Chemicals Order No. 22.10 or 19.10) or own sources.
  • the latter is an E. coli XL10 Gold clone which contains in the plasmid pUC19 the glucose dehydrogenase gene from Bacillus subtilis (Genbank Acc Nos M12276) (this construct is named E. coli LU11293).
  • Each 150 mL of medium was sterilized in two 1 L Erlenmeyer flasks and completed with 5 mL of sterile saline. After inoculating from an LB ampicillin agar plate, the precultures were incubated at 37 ° C and 200 rpm for 12 hours and added to the fermentation medium. The fermentation was started at 37 ° C., 0.1 bar internal pressure, pH 7.0 (control with 20% phosphoric acid and 25% NaOH) with a gassing rate of 7.5 L / min and 300 rpm (regulation pO 2 between 20 and 50% with 10-20 L / min supply air and 500-1500 rpm).
  • the regeneration of the cofactor can also be carried out by the phenylethanol dehydrogenase. In this case, the addition of a separate regeneration enzyme is not necessary.
  • the phenylethanol dehydrogenase accepts various simple alcohols as reducing agents. They are oxidized to the corresponding carbonyl compounds.
  • a simple alcohol suitable for the regeneration of NADH with phenylethanol dehydrogenase is isopropanol. If 10% isopropanol is used instead of glucose dehydrogenase and glucose in the reaction mixture, the activity of the phenylethanol dehydrogenase can be determined as shown in Example 2.
  • E. coli LU11558 was grown as in Example 1, harvested and made into crude cell-free extract. This was mixed with 0.2 mM NAD + and 5.4 mL of a 1.68 M sodium 3,5,5-trimethyl-1,4-dioxo-cyclohex-2-en-2-olate solution (Compound 1a) and incubated at 30 ° C for 48 h.
  • Example 7 Preparation of (4S) -4-hydroxy-3-methoxy-2,6,6-trimethylcyclohex-2-enone with a recombinant dehydrogenase from Azoarcus sp EbN1
  • E. coli LU11558 was grown as in Example 1, harvested and made into crude cell-free extract. This was admixed with 0.2 mM NAD + and 5.4 ml of a 1.68M sodium 3,5,5-trimethyl-1,4-dioxo-cyclohex-2-en-2-olate solution and left at 30 for 48 h ° C incubated. Cell-free crude extract of E.
  • the reaction was monitored by HPLC analysis. After 7 hours, the amount of starting material was increased by the addition of 3.6 g of 2-methoxy-3,5,5-trimethylcyclohex-2-en-1,4-dione. After 75 hours, the starting material was consumed to more than 60%.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (9)

  1. Procédé pour la préparation de dérivés optiquement actifs de la (4S)-4-hydroxy-2,6,6-triméthylcyclohex-2-én-1-one de formule (I)
    Figure imgb0013
     où
    R1 représente hydrogène, C1-C10-alkyle, C7-C14-arylalkyle, un métal alcalin M1 ou un fragment de métal alcalino-terreux M2 1/2 ou (M2)+X-, où M1 représente Li, Na, K, Rb ou Cs et M2 représente Mg, Ca, Sr ou Ba et X- signifie un anion monochargé,
    comprenant une étape de réaction,
    dans laquelle on incube dans un milieu qui contient un dérivé de triméthylcyclohex-2-ène-1,4-dione de formule (II),
    Figure imgb0014
     dans laquelle R2 est identique ou différent de R1 et représente hydrogène, C1-C10-alkyle, C7-C14-arylalkyle, un métal alcalin M1 ou un fragment de métal alcalino-terreux M2 1/2 ou (M2)+X-, où M1 représente Li, Na, K, Rb ou Cs et M2 représente Mg, Ca, Sr ou Ba et X- signifie un anion monochargé,
    une enzyme (E), qui présente une séquence polypeptidique
    (i) qui présente la séquence SEQ ID NO : 2, ou
    (ii) dans laquelle jusqu'à 25% des restes d'acides aminés sont modifiés par rapport à la séquence SEQ ID NO :2 par délétion, insertion, substitution ou une combinaison de celles-ci et qui présente encore au moins 50% de l'activité enzymatique de la SEQ ID NO :2,
    en présence d'équivalents de réduction, où le composé de formule (II) est réduit enzymatiquement en composé de formule (I) et les équivalents de réduction consommés au cours de la réaction sont à nouveau régénérés par transformation d'un agent de réduction (RM) en produit d'oxydation correspondant (OP) à l'aide de l'enzyme (E) ou d'une autre enzyme (E2) et le produit d'oxydation (OP) est éventuellement éliminé, du moins partiellement, du milieu de réaction ou de l'équilibre de réaction, et on isole le produit (I) formé.
  2. Procédé selon la revendication 1, l'enzyme étant codée par une séquence d'acides nucléiques selon la séquence SEQ ID NO :1 ou un équivalent fonctionnel de celle-ci.
  3. Procédé selon l'une quelconque des revendications précédentes, où on utilise comme agent de réduction (RM) un composé organique qui contient au moins une fonction alcool primaire ou secondaire CH(OH), en particulier l'isopropanol ou le glucose.
  4. Procédé selon l'une quelconque des revendications précédentes, où la transformation du composé de formule (II) est réalisée en présence d'un microorganisme, qui est choisi parmi les bactéries des familles des Enterobacteriaceae, des Pseudomonadaceae, des Rhizobiaceae, des Lactobacillaceae, des Streptomycetaceae, des Rhodococcaceae, des Rhodocyclaceae et des Nocardiaceae.
  5. Procédé selon l'une quelconque des revendications précédentes, où le microorganisme est un microorganisme recombinant, qui est transformé avec un élément d'acide nucléique qui code pour une enzyme selon la définition dans la revendication 1.
  6. Procédé selon l'une quelconque des revendications précédentes, où R1 dans la formule (I) représente hydrogène, méthyle ou sodium, en particulier hydrogène ou sodium.
  7. Procédé pour la préparation de (3S,3'S)-astaxanthine comprenant un procédé selon l'une quelconque des revendications comme une étape de réaction de la synthèse totale de la (3S,3'S)-astaxanthine.
  8. Utilisation d'une enzyme (E) présentant une séquence polypeptidique
    i. qui présente la séquence SEQ ID NO : 2, ou
    ii. dans laquelle jusqu'à 25% des restes d'acides aminés sont modifiés par rapport à la séquence SEQ ID NO :2 par délétion, insertion, substitution ou une combinaison de celles-ci et qui présente encore au moins 50% de l'activité enzymatique de la SEQ ID NO :2,
    pour la préparation d'un composé de formule (I).
  9. Utilisation selon la revendication 8, où le composé de formule (I) est transformé dans d'autres étapes de réaction en (3S, 3'S)-astaxanthine de formule (III).
EP07822458A 2006-11-10 2007-11-09 Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus Not-in-force EP2089530B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07822458A EP2089530B1 (fr) 2006-11-10 2007-11-09 Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06123814 2006-11-10
PCT/EP2007/062170 WO2008055988A2 (fr) 2006-11-10 2007-11-09 Procédé de production de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2énone et de ses dérivés
EP07822458A EP2089530B1 (fr) 2006-11-10 2007-11-09 Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus

Publications (2)

Publication Number Publication Date
EP2089530A2 EP2089530A2 (fr) 2009-08-19
EP2089530B1 true EP2089530B1 (fr) 2010-03-03

Family

ID=39321502

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07822458A Not-in-force EP2089530B1 (fr) 2006-11-10 2007-11-09 Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus

Country Status (8)

Country Link
US (1) US20090325225A1 (fr)
EP (1) EP2089530B1 (fr)
CN (1) CN101535495A (fr)
AT (1) ATE459723T1 (fr)
DE (1) DE502007003046D1 (fr)
ES (1) ES2340889T3 (fr)
TW (1) TW200846473A (fr)
WO (1) WO2008055988A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2142494A1 (fr) * 2007-03-28 2010-01-13 Basf Se Procede de production enantioselective de derives optiquement actifs de 4-hydroxy-2,6,6-trimethylcyclohex-2-enone
JP5503534B2 (ja) 2007-06-20 2014-05-28 ビーエーエスエフ ソシエタス・ヨーロピア アゾアルクス（Ａｚｏａｒｃｕｓ）ＳｐＥｂＮ１脱水素酵素を用いる光学活性アルコールの製造方法
EP2145904A1 (fr) 2008-07-18 2010-01-20 Basf Se Procédé d'hydrolyse catalysée par enzymes d'esters d'acide polyacrylique et estérases utilisées à cet effet
CA2735769C (fr) 2008-09-17 2018-10-09 Basf Se Procede de preparation d'alcools optiquement actifs
CN110121489A (zh) * 2016-12-19 2019-08-13 巴斯夫欧洲公司 制备(4s)-或(4r)-3,4-二羟基-2,6,6-三甲基环己-2-烯酮的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004022686A1 (de) * 2004-05-05 2005-11-24 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
EP2142494A1 (fr) * 2007-03-28 2010-01-13 Basf Se Procede de production enantioselective de derives optiquement actifs de 4-hydroxy-2,6,6-trimethylcyclohex-2-enone

Also Published As

Publication number Publication date
EP2089530A2 (fr) 2009-08-19
ATE459723T1 (de) 2010-03-15
WO2008055988A2 (fr) 2008-05-15
TW200846473A (en) 2008-12-01
US20090325225A1 (en) 2009-12-31
DE502007003046D1 (de) 2010-04-15
ES2340889T3 (es) 2010-06-10
WO2008055988A3 (fr) 2008-07-31
CN101535495A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
EP1929001B1 (fr) Nouvelles deshydrogenases, leurs derives, et un procede pour produire des alcanols optiquement actifs
EP1963516B1 (fr) Procede de reduction enzymatique enantioselective de composes hydroxyceto
EP2089530B1 (fr) Procédé de préparation de (4s)-3,4-dihydroxy-2,6,6-triméthyl-cyclohex-2-énone et de ses dérivés en utilisant la phényléthanol déshydrogénase de azoarcus
EP3274465B1 (fr) Production bio-catalytique de fucose l
KR100946461B1 (ko) 1,1,1-트라이플루오로아세톤의 비대칭 환원
WO2008064817A2 (fr) Procédé de synthèse stéréosélective d'époxydes chiraux par réduction adh de cétones substituées avec des groupes partants alpha, et cyclisation
EP1969133B1 (fr) Procede de production de (1s)-3-chlor-1-(2-thienyl)-propan-1-ole optiquement actif
DE60115849T2 (de) Methode und katalytisches system zur stereoselektiven invertierung eines chiralen zentrums in einer chemischen verbindung
DE102006039189B4 (de) Enantioselektive Darstellung von aliphatischen azyklischen Estern und Ketonen
CN112176007B (zh) 一种氨基醇手性中间体的制备方法
US7294492B2 (en) Process for the manufacture of spiroketals
EP1313870B1 (fr) Procede permettant d'ameliorer la preparation et l'isolation d'acides carboxyliques i trans /i -dihydroxycyclohexadiene et/ou de leurs derives, et organisme genetiquement modifie approprie
DE69730444T2 (de) Verfahren zur herstellung optisch aktiven n-benzyl-3-pyrrolidinols
EP1805314B1 (fr) Procede d'ouverture enantioselective des oxetan-2-ones 3-substituees en utilisant les lipases de candida antarctica ou de burkholderia plantarrii
DE10032254A1 (de) Nukleotidsequenz kodierend für eine Benzaldehyd-Lyase und Verfahren zur stereoselektiven Synthese von 2-Hydroxyketonen
DE60309830T2 (de) Verfahren zur herstellung von chiralen aromatischen alpha-hydroxy-ketonen unter verwendung einer 2-hydroxy-3-oxosäure-synthase
DE10152113C1 (de) Verfahren zur Herstellung von (R)- und (S)-8-Chlor-6-hydroxy-octansäurealkylestern durch enzymatische Reduktion
WO2008074506A1 (fr) Résolution optique d'un mélange d'énantiomères de butynol ou de buténol
EP2193194B1 (fr) Procédé de préparation de 2-méthyl-1,2-dihydroxypropane
DE102008064574B4 (de) Verfahren zur Herstellung von 2R1(S)-1-on-Verbindungen mittels Enon-Reduktion
EP4431612A1 (fr) Procédé de préparation de corrytuberine et salutaridine
DE102005038606A1 (de) Verfahren zur enzymatischen Herstellung von chiralen 1-acylierten 1,2-Diolen
DE102007045092A1 (de) Enzymsystem mit der Aktivität einer Monooxygenase und Verfahren zur Oxidation von Methylgruppen in aliphatischen Kohlenwasserstoffen
DE102012022670A1 (de) Verfahren zur Herstellung enantiomerenangereicherter und enantiomerenreiner Nitroalkane und Amine
TW201311648A (zh) 製造光學活性（ｒ）－（－）－１－（２，４－二氯－苯基）－２－咪唑－１－基－乙醇的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090610

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: PROCESS FOR THE PREPARATION OF (4S)-3,4-DIHYDROXY-2,6,6-TRIMETHYL-CYCLOHEX-2-ENONE AND DERIVATIVES THEREOF EMPLOYING THE AZOARCUS PHENYLETHANOL DEHYDROGENASE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

DAX Request for extension of the european patent (deleted)
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 502007003046

Country of ref document: DE

Date of ref document: 20100415

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2340889

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100604

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100603

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100703

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100705

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20101214

Year of fee payment: 4

Ref country code: NL

Payment date: 20101124

Year of fee payment: 4

26N No opposition filed

Effective date: 20101206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

BERE Be: lapsed

Owner name: BASF SE

Effective date: 20101130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20110131

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101228

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120601

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20111109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120601

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502007003046

Country of ref document: DE

Effective date: 20120601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101109

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111109

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111110

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 459723

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130